July 18, 2007 / Research Triangle Park, NC and Vancouver, Canada — The Canadian Retinal Trials Group has standardized on Clinipace’s clinical software platform, Tempo, to support its upcoming research projects. The Canadian Retinal Trials Group (CRTG), founded by Dr. David Maberley of the University of British Columbia’s renowned retinal department, is a research network of 12 leading academic and institutional medical centers throughout Canada established to rapidly and efficiently conduct clinical studies.
For this initial study, CRTG will use Tempo to collect and manage data on over 100 patients over the course of 2 years whom have been diagnosed with Neovascular Age-Related Macular Degeneration (AMD). Specifically, the study will examine the use of Avastin, an anti-angiogenic drug being administered to patients as an intravitreal injection, in combination with other existing standard therapies.
Dr. David Maberley, an investigator in the Avastin study and director of the Canadian Retinal Trials Group, explains the organization’s decision to use Clinipace’s Tempo platform, “Selecting Clinipace’s Tempo as our technology platform was a significant step in establishing a collaborative infrastructure for our 12-site network. It was important for us to standardize on a technology platform that was easy for our investigators to use in order to leverage the network immediately and effectively.”
AMD is a degenerative disease of the central part of the eye’s retina, is the leading cause of irreversible blindness in developed countries throughout the world. In Canada, in 1993, AMD accounted for 54% of new diagnoses for clients registering with the Canadian National Institute for the Blind. Furthermore, as the North American population ages, it is predicted that the number of cases of AMD in the United States would increase from 2.7 million in 1970 to 7.5 million by 2020.
Jeff Williams, Chief Executive Officer of Clinipace, adds, “This is an exciting opportunity for Clinipace to be part of the foundation of this network of top-tier research institutions. Supporting a network running multiple studies is an ideal use of the Tempo platform, and CRTG will continue to experience gains in efficiency with each subsequent study, dramatically stretching the research dollar.”
Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace, please visit: www.clinipace.com
The Canadian Retinal Trials Group was formed in 2003 under the direction of Dr David Maberley, Associate Professor with the University of British Columbia’s Department of Ophthalmology and Visual Sciences. Formed as a consortium of leading retinal specialists across Canada, the goal is to foster national collaborative multi-centre research about clinically important questions arising in retinal disease. In particular, the CRTG will endeavor to elaborate studies needed to increase the level of evidence for non-proprietary interventions that would not normally be evaluated by corporate entities.